AstraZeneca PLC (AZN) Announced Positive Results for its Phase 3 Trial of Gefurulimab

AstraZeneca PLC (NASDAQ:AZN) is one of the Stocks With Huge Catalysts on the Horizon. On July 24, AstraZeneca PLC (NASDAQ:AZN) announced positive results for its global Phase 3 trial of Gefurulimab in adults with generalized myasthenia gravis who are antibody-positive.

Management noted that the trial was randomized, double-blind, and placebo-controlled. It met its primary and all secondary endpoints as patients showed significant improvement in their daily activities related to gMG at 26 weeks compared to placebo. gMG is a rare autoimmune disease that causes muscle weakness and loss of function. CEO of AstraZeneca PLC (NASDAQ:AZN) Rare Disease Marc Dunoyer noted that the results confirm gefurulimab’s potential as a fast-acting and sustained treatment option. Management expects the treatment to become first-line with a good safety profile.

AstraZeneca PLC (NASDAQ:AZN) is a biopharmaceutical company that focuses on oncology, rare diseases, cardiovascular, respiratory, immunology, and vaccines.

While we acknowledge the potential of AZN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.